| Identification | Back Directory | [Name]
MECLOFENAMATE SODIUM | [CAS]
6385-02-0 | [Synonyms]
ci583
Movens
C02996
meclomen
Meclonax
Meclofenamate
SODIUM MECLOFENAMATE
sodiummeclophenamate
MECLOFENAMATE SODIUM
MECLOFENAMATESODIUM,USP
meclofenamic acid sodium
MECLOFENAMATE SODIUM SALT
SodiuM MeclofenaMate
Sodium Meclofenamate Hydrate
MECLOFENAMATE SODIUM HYDRATE
MECLOFENAMIC ACID SODIUM SALT
Meclofenamate Sodium (500 mg)
MECLOFENAMATE SODIUM USP/EP/BP
sodium meclofenamate (anhydrous)
Sodium Meclofenamate Monohydrate
MECLOFENAMIC ACID SODIUM SALT 99%
SodiumMeclofenamateMonohydrate>
MECLOFENAMIC ACID SODIUM SALT MONOHYDRATE
sodium,2-(2,6-dichloro-3-methylanilino)benzoate
Meclofenamate Sodium (Meclofenamic acid sodium)
sodium2-((2,6-dichloro-3-methylphenyl)amino)benzoate
n-(2,6-dichloro-m-tolyl)-anthranilicacimonosodiumsalt
sodium 2-(2,6-dichloro-3-methylanilino)benzoate hydrate
2-[(2,6-DICHLORO-3-METHYLPHENYL)AMINO]BENZOIC ACID SODIUM SALT
2-((2,6-dichloro-3-methylphenyl)amino)-benzoicacimonosodiumsalt
Benzoic acid, 2-[(2,6-dichloro-3-Methylphenyl)aMino]-, sodiuM salt
2-[(2,6-DICHLORO-3-METHYLPHENYL)AMINO]-BENZOIC ACID, MONOSODIUM SALT
2-[(2,6-dichloro-3-methylphenyl)amino]-benzoic acid, sodium salt (1:1)
Benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino]-, sodium salt (1:1)
2-[(2,6-Dichloro-3-methylphenyl)amino]benzoic acid sodium salt monohydrate
2-[(2,6-Dichloro-3-methylphenyl)amino]benzoic Acid Sodium Salt
Meclofenamic Acid Sodium Salt | [EINECS(EC#)]
228-983-3 | [Molecular Formula]
C14H10Cl2NO2.Na | [MDL Number]
MFCD00941475 | [MOL File]
6385-02-0.mol | [Molecular Weight]
318.13 |
| Chemical Properties | Back Directory | [Melting point ]
287-291 °C | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
White solid. | [color ]
White to Off-White | [biological source]
synthetic (organic) | [Water Solubility ]
Soluble in water at 50mg/ml. Also soluble in DMF, DMSO or ethanol | [Merck ]
14,5779 | [Stability:]
Hygroscopic | [Major Application]
pharmaceutical | [InChI]
1S/C14H11Cl2NO2.Na.H/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;;/h2-7,17H,1H3,(H,18,19);; | [InChIKey]
CHGIZYUDGOIAFY-UHFFFAOYSA-N | [SMILES]
[Na].Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl |
| Hazard Information | Back Directory | [Description]
Meclofenamate is a time-dependent, non-specific competitive inhibitor of COX-1 and -2. The IC50 values for inhibition of human recombinant COX-1 and -2 are 1.5 and 9.7 μM, respectively for instantaneous inhibition. However, the IC50 is much lower if pre-incubated with the enzyme.1 | [Originator]
Meclomen,Warner Lambert,US,1980 | [Uses]
antiinflammatory, antipyretic | [Definition]
ChEBI: An organic sodium salt derived from meclofenamic acid. Its monohydrate is used for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | [Indications]
Meclofenamate sodium (Meclomen) is
prescribed for rheumatoid arthritis and osteoarthritis.
The fenamates show no clear superiority in antiinflammatory
activity and may produce more adverse
effects than other NSAIDs. | [Manufacturing Process]
A mixture consisting of 22.7 g potassium o-bromobenzoate, 16.6 g 2,6- dichloro-3-methylaniline, 12 ml N-ethylmorpholine, 60 ml diethylene glycol dimethyl ether, and 1.0 g anhydrous cupric bromide is heated in a nitrogen atmosphere at 145°C to 155°C for 2 hours. The reaction mixture is diluted with 60 ml diethylene glycol dimethyl ether and acidified with 25 ml concentrated hydrochloric acid. The acidic mixture is diluted with 100 ml of water and the liquid phase decanted from the insoluble oil. The insoluble oil is stirred with methanol and the crystalline N-(2,6-dichloro-3-methylphenyl) anthranilic acid which separates is collected and washed with methanol. The product, after recrystallization from acetone-water mixture, melts at 248°C to 250°C. | [Brand name]
Meclomen (Parke-Davis). | [Therapeutic Function]
Antiinflammatory | [General Description]
Meclofenamate sodium (Meclomen) is available for use inthe treatment of acute and chronic RA, OA, and primarydysmenorrhea. It is metabolized in a similar manner tomefenamic acid discussed above, thus a similar restriction isalso applied to meclofenamate. The most significant side effectsare GI, including diarrhea. | [Biological Activity]
Dual 5-lipoxygenase (IC50=46.8 μM) and cyclooxygenase I and II inhibitor (IC50=0.6 μM). Clinically useful NSAID. | [Pharmacokinetics]
Meclofenamate sodium is rapidly and almost completely absorbed following oral administration, reaching peak plasma
levels within 2 hours. It is highly bound to plasma proteins (99%) and has a plasma half-life of 2 to 4 hours.
Metabolism involves oxidation of the methyl group, aromatic hydroxylation, monodehalogenation, and conjugation.
Urinary excretion accounts for approximately 75% of the administered dose. The major metabolite is the product of
3′-methyl oxidation and has been shown to possess anti-inflammatory activity.
 | [Clinical Use]
Meclofenamate sodium is indicated for the relief of mild to moderate pain, the acute and chronic treatment of
rheumatoid arthritis and osteoarthritis, the treatment of primary dysmenorrhea, and the treatment of idiopathic, heavy
menstrual blood loss. |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
| Company Name: |
Maya High Purity Chemicals
|
| Telephone: |
+86 (573) 82222445 (0)18006601000 452520369 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15221/0_EN.htm |
| Company Name: |
parabiochem
|
| Telephone: |
025-83453382-8005 |
| Website: |
www.parabiochem.cn |
|